- Home
- YI vs ELUT Comparison
YI vs ELUT Comparison
Compare YI & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YI | ELUT |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 45.8M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | YI | ELUT |
|---|---|---|
| Price | $6.43 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 14.1K | ★ 153.5K |
| Earning Date | 03-20-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | ★ N/A | $1.23 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.48 | $0.50 |
| 52 Week High | $11.17 | $2.99 |
Technical Indicators
Market Signals| Indicator | YI | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 48.02 |
| Support Level | $6.13 | $0.86 |
| Resistance Level | $6.86 | $1.16 |
| Average True Range (ATR) | 0.46 | 0.09 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 32.08 | 21.54 |
Price Performance
Historical ComparisonAbout YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.